Intensive Blood Pressure Management Reduces Recurrent Stroke After Intracerebral Hemorrhage

Intracerebral hemorrhage (ICH), or bleeding within brain tissue, carries high early mortality and leaves survivors at substantial risk of recurrent stroke. Secondary prevention remains challenging because long-term blood pressure targets and treatment strategies vary in clinical practice, while persistent gaps in hypertension control can complicate care from hospitalization through follow-up. To address this challenge, researchers have evaluated whether more intensive, sustained blood pressure management can reduce recurrent events in ICH survivors.

Led by The George Institute for Global Health, the RECAP-ICH individual participant data meta-analysis assessed intensive, long-term blood pressure-lowering treatment after ICH. Published in The Lancet Neurology in 2026, the study examined whether tighter blood pressure control could reduce recurrent stroke without increasing harm among adults who had survived an ICH and were receiving outpatient secondary prevention.

Researchers pooled data from four randomized controlled trials involving 2,944 adults. Two trials used fixed-dose antihypertensive combinations, while two employed treatment strategies guided by prespecified blood pressure targets. Follow-up extended for up to six years. The TRIDENT study, led by The George Institute for Global Health, was the only trial to exclusively enroll patients with spontaneous ICH; the other studies included participants with both ischemic and hemorrhagic stroke at baseline.

Across the four trials, recurrent stroke occurred in 6.5% of patients assigned to intensive treatment compared with 10.4% receiving less intensive or standard care, representing a 38% relative reduction. The benefit was consistent across studies and was associated with a mean systolic blood pressure (SBP) of 127 mm Hg in the intensive-treatment group versus 138 mm Hg in controls, a difference of 11.2 mm Hg. Much of the reduction in recurrent stroke was driven by an approximately 61% lower rate of recurrent ICH. Serious adverse events occurred in about 29% of patients receiving intensive therapy and 33% of controls.

Subgroup analyses indicated that the benefit was not dependent on the time elapsed since the initial ICH and was observed across baseline SBP levels. Importantly, patients who began treatment with blood pressure already within conventional target ranges still faced considerable risk. Among those with baseline SBP at or below 130 mm Hg, recurrent stroke occurred in 13.9% of patients receiving standard care compared with 6.2% under intensive management. The findings support active treatment titration to achieve and sustain lower blood pressure over time rather than relying solely on baseline measurements.

Globally, more than three million people experience ICH each year, while an estimated 17 million are living after an ICH, with roughly one-quarter subsequently dying from recurrent stroke or cardiovascular disease. The burden is greatest in low- and middle-income countries, where ICH rates are nearly twice those seen in high-income settings and hypertension control is often suboptimal. The findings underscore the importance of structured, sustained antihypertensive management throughout the continuum of care to reduce the risk of recurrent stroke.

“Intracerebral hemorrhage is one of the deadliest forms of stroke, with limited treatment options and a high risk of recurrence among survivors. Our analysis shows that intensive blood pressure treatment can prevent 16 recurrent strokes for every 1,000 patients treated within the first year alone. These findings reinforce the central role of blood pressure control in secondary stroke prevention,” said Professor Craig Anderson, senior author and senior professorial fellow at The George Institute.

“Generally, guidelines recommend treatment to a target of less than 130/80 mm Hg, but our study showed that patients at or below this threshold can still face a significant risk of recurrent stroke. Preventing stroke recurrence requires us to address the persistent barriers to blood pressure control, such as poor treatment adherence and therapeutic inertia. To achieve reliable control, we need to continue pursuing approaches that have shown promise, including fixed-dose combination therapies and structured treatment titration protocols,” added Anderson.

Related Links
The George Institute for Global Health